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Optimal care for breast cancer patients undergoing aromatase inhibitor (AI) treatment is ensured when estradiol (E2)
levels are adequately suppressed. To assess treatment efficacy accurately, it is important to measure the serum E2 levels
using a well validated assay method with high sensitivity and specificity. This translates into the urgent need to
evaluate various E2 immunoassay kits, which are frequently used in hospital settings to measure E2 serum levels in
patients undergoing AI treatment, so clinicians obtain accurate and reliable measurements allowing appropriate clinical
decision making. Our objective was to evaluate the performance of different commercially available and commonly
used E2 immunoassay kits regarding measurement of E2 levels in the serum of postmenopausal breast cancer patients
treated with AIs, in comparison to a highly accurate and reliable mass spectrometry assay. Clinical and demographic
data were obtained from 77 postmenopausal breast cancer patients who were treated with an AI. Serum E2 levels were
measured by 6 immunoassay methods and by liquid chromatography-tandem mass spectrometry (LC-MS/MS), which
served as the standard for comparison. Analysis of E2 by LC-MS/MS showed that 70% of the samples had levels that
were <5 pg/ml. Three of the assays carried out with commercial E2 immunoassay kits had poor sensitivities and were
not able to detect E2 levels <10 or <20 pg/ml. Although two of the E2 assays using commercial kits demonstrated a
better sensitivity (5 pg/ml), the measured E2 values were substantially higher than those obtained by LC-MS/MS. The
assay with the sixth commercial E2 kit grossly underestimated the true E2 values. E2 assays carried out with commercial
E2 immunoassay kits lack the accuracy to measure the very low serum E2 levels found in patients being treated with
AIs. Serum samples from such patients should be sent to laboratories that use a mass spectrometry assay.Introduction
Hormone suppression in postmenopausal women with
estrogen or progesterone receptor positive breast can-
cers has been associated with significant benefits such
as decreased local and distant recurrences, a lower risk
of contralateral breast cancer and improved breast
cancer specific mortality (Coates et al. 2007; Forbes
et al. 2008). In patients with early breast cancer, adjuvant
therapy with aromatase inhibitors (AIs) was proven to
lower 5-year relapse rates with improved side effect profiles* Correspondence: jennyja@usc.edu
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in any medium, provided the original work is pover alternative medications such as tamoxifen (Howell
et al. 2005). Even women with metastatic disease benefit
from slowed disease progression due to AI treatment.
Therefore, AIs play a major role in the adjuvant treatment
of estrogen receptor positive breasts cancers in postmeno-
pausal patients.
In postmenopausal women, the primary source of
estrogen is adipose tissue. Here, the enzyme aromatase
converts testosterone and androstenedione into estradiol
(E2) and the weaker estrogen, estrone, respectively. Third
generation AIs suppress aromatase activity by 90 – 99%,
which leads to a reduction of circulating estrogen levels to
1% to 10% compared with pretreatment levels (Santen et al.
2007). By decreasing systemic estrogen significantly,n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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micrometastases and dormant cancer cells (Howell
et al. 2005). Hence, full benefits and optimal treatment
outcome of postmenopausal breast cancer patients depend
on maximally suppressed E2 levels.
During AI treatment, mean (± standard deviation) serum
levels of E2 have been reported to be 5.8 ± 4.1 pg/ml, as
measured by radioimmunoassay (RIA) with preceding
purification steps (Santen et al. 2007). To assess treatment
efficacy correctly, it is important to measure these low E2
levels using an accurate and reliable assay method with
high sensitivity and specificity such as gas or liquid
chromatography-tandem mass spectrometry (GC-MS/MS
or LC-MS/MS). Although being the purported “gold
standard” for measuring low serum levels of E2, mass
spectrometry is only available in a relatively small number
of clinical diagnostic laboratories because it is a highly
specialized and an expensive assay method (Stanczyk &
Clarke 2010).
In most hospital settings, E2 measurements are obtained
by a direct immunoassay technique. Using kits provided by
various manufacturers, direct immunoassays are easy to
carry out, allow automated performance and require only a
small sample volume. However, direct immunoassays lack a
purification step to remove metabolites that may potentially
cross-react with the antibody in the assay (Stanczyk et al.
2010; Stanczyk et al. 2003). Hence, E2 levels in serum from
patients treated with AIs may be measured significantly
higher by direct immunoassay than by a mass spectrometry
assay. These incorrectly elevated results can be attributed
to the lower specificity of the direct immunoassay
compared to mass spectrometry.
Thus, when comparing the specificity of a mass
spectrometry assay versus a direct immunoassay, E2 levels
in serum from patients treated with AIs may be measured
significantly higher by direct immunoassay than by a mass
spectrometry assay. Hence, direct immunoassays may yield
incorrectly elevated results.
Another limitation of direct E2 immunoassays using com-
mercial kits is that only a single small aliquot (0.1 ml) of
serum can be used in the assay, as based on the procedure
established by the kit manufacturer. Larger serum aliquots
would compensate for a less sensitive E2 assay when very
low E2 levels are being measured.
Inaccurate measurements of systemic E2 levels in a
patient undergoing AI treatment may falsely indicate
that the treatment goal is not reached, which can lead to
a change in therapy. Subsequently, serious side effects
could result such as rapid bone density loss or cardio-
vascular events in women with preexisting heart disease
(Amir et al. 2011). In order to address this clinical need
for correct E2 measurements, the objective of the
present study was to evaluate the accuracy of several
different commercially available and commonly used E2immunoassay kits regarding measurement of E2 levels




Study participants were naturally or surgically postmeno-
pausal women, who had a diagnosis of breast cancer veri-
fied by histology. Seventy-seven patients were identified at
the Medical Oncology service at the Los Angeles County
and University of Southern California Medical Center
(Los Angeles, CA), and were being treated with an aroma-
tase inhibitor, which included either Arimidex (N = 63),
Letrozole (N = 7), Femara (N = 4), or Aromasin (N = 3).
The ages of the participants ranged from 33 to 79 years,
and their BMI ranged from 16.2 to 49.4 kg/m2.
This study was approved by the Institutional Review
Boards at USC.
Blood sampling
A single blood sample (10 ml) was obtained from each sub-
ject and allowed to clot for 1–2 hours. After centrifugation
of the sample, the serum was removed and stored at −20°C.
Assay methods
Reference assay
The E2 LC-MS/MS assay was carried out at Quest
Diagnostics Nichols Institute (San Juan Capistrano,
CA). Each sample is prepared by adding 300 μL of 30%
aqueous ethanol solution and 50 μL of the internal
standard solution (which consists of the deuterated
estradiol in methanol) to 200 μL of the serum. The ethanol
solution is used to break up the ionic interaction from the
carrier protein to release the analyte without precipitating.
After vigorous mixing, the samples are incubated at room
temperature for 15 to 20 minutes prior to being placed in
the refrigerated autosampler for injection into the Aria
TLX System (Thermo Fisher, San Jose, CA). Following
injection, the sample is loaded onto a high flow rate extrac-
tion column. This creates turbulence inside the column,
which allows the steroids to bind to the large particles of
the extraction column, while protein and other debris freely
flow through and are discarded. Following the loading step,
the flow is reversed and the sample is eluted off the extrac-
tion column and transferred to a reverse-phase ether-linked
phenyl analytical column. A binary HPLC gradient is ap-
plied to the column resulting in the separation of estradiol
from its metabolites.
E2 is then quantitated using a TSQ Quantum Ultra
triple quadrupole tandem mass spectrometer (Thermo
Fisher, San Jose, CA). The tandem mass spectrometer per-
mits the isolation of the parent compound within ± 0.5 m/z
in the first quadrupole (Q1). In the second quadrupole
(Q2), the parent ions collide with an inert gas (argon) to
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quadrupole (Q3).
The sensitivity of the LC-MS/MS assay is 2 pg/ml; the
intraassay coefficients of variation (CVs) are 15.3%,
10.4% and 7.6% at 10 pg/ml, 200 pg/ml and 800 pg/ml,
respectively; the interassay CVs are 7.7-15.3%, 9.9-14.0%
and 4.2-10.5% at 10 pg/ml, 200 pg/ml and 800 pg/ml,
respectively.
Evaluated assays
Six different commercial immunoassay kits for measuring
E2 were evaluated. The source and type of assays obtained
with each of the kits are specified in Table 1. Four of the E2
kits (Beckman Coulter Ultra-Sensitive, Siemens Healthcare
Diagnostics Coat-A-Count and Double Antibody, and
Pantex Extraction125I) required radioimmunoassay (RIA)
methodology, which was carried out manually, and the
other two (Siemens Healthcare Diagnostics Immulite 2000
and Roche Diagnostics Elecsys 2010) required chemilumin-
escent immunoassay methodology using an automated
analyzer. Only the assay using reagents from the Pantex
Extraction125I kit required a preceding purification step.
Validation of the E2 assays with the 6 different
kits, as based on the assay performance characteris-
tics described in the package insert accompanying
each kit, can be summarized as follows. Assay preci-
sion and linearity are acceptable. To validate assay
specificity only a limited number of E2 metabolites
were evaluated for cross-reactivity, and no compari-
son was made to an E2 immunoassay with preceding
organic solvent extraction and chromatography steps.
The assay sensitivity for each kit is shown in Table 1,
but no information is given about how the assay
sensitivity was determined. Finally, assay accuracy
was not determined by comparing E2 values obtained
with the kits to corresponding values obtained with
a mass spectrometry assay.Table 1 Source and description of commercial E2 kits used to


























Pantex Extraction RIA with preceding extracti
(Santa Monica, CA) 125I Estradiol RIA
* represents sensitivity of the evaluated assay.Results
LC-MS/MS reference assay
All 77 samples were quantified by LC-MS/MS assay. Of the
76 E2 measurements obtained by LC-MS/MS, 46 were
below the sensitivity of the assay, which is 2 pg/ml. Another
10 values ranged between <2-5 pg/ml. Thus, approximately
73% of the values were <5 pg/ml. The remaining values
ranged between 5–20 pg/ml. Figure 1 displays the degree of
agreement between LC-MS/MS levels and the other 6 assay
methods.
One of the E2 values measured by LC-MS/MS was very
high (133 pg/ml) and clearly an outlier, most likely due to
the patient not taking the aromatase inhibitor drug on the
blood-sampling day. Consequently, the E2 results for that
sample are excluded from the results of each of the assay
methods.
Kits from Siemens Healthcare Diagnostics
Three of the E2 assay methods involved use of reagent
kits from Siemens Healthcare Diagnostics.
Siemens Healthcare Diagnostics Immulite 2000 Kit
The assay carried out by chemiluminescent immunoassay
using the Immulite 2000 kit has a sensitivity of 20 pg/ml
according to the manufacturer, which is the same as the
lowest point on the standard curve. A total of 72 out of 76
samples had E2 levels that were <20 pg/ml, and therefore
no actual values below 20 pg/ml could be reported for the
72 samples (Figure 1, column 1). Four samples that were
below 6 pg/ml by LC-MS/MS had levels between 21 and
44 pg/ml.
Siemens Healthcare Diagnostics Double Antibody RIA Kit
The E2 assay with the Siemens Double Antibody RIA kit
has a sensitivity of 1.4 pg/ml according to the kit manu-
facturer, but the lowest E2 point on the standard curve has
a concentration of 5 pg/ml. A total of 70 of the 76measure E2 following aromatase inhibitor treatment
Sensitivity reported
by manufacturer
Lowest E2 Concentration on
Standard Curve in our study*
assay
20 20





on Step 10 10
Figure 1 Percent agreement of E2 values obtained by the 6 different immunoassay methods with the corresponding values measured
by LC-MS/MS. Each bar graph shows the proportion of E2 values that are unknown (could not be compared to the LC-MS/MS values due to
insufficient assay sensitivity), lower, in agreement, and/or higher than the values obtained by the mass spectrometry assay. Percent agreement of
E2 values obtained by different immunoassay methods with the corresponding values measured by LC-MS/MS.
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cluding 17 values that were above 6 pg/ml with LC-MS/
MS (Figure 1, column 2). Two of the E2 values were
very high (242 and 316 pg/ml) and are most likely due
to cross-reactivity of the antibody with interfering sub-
stances in the serum samples. Four other samples had E2
values exceeding LC-MS/MS levels by 4 – 58 pg/ml.Siemens Healthcare Diagnostics Coat-A-Count RIA Kit
The sensitivity of the E2 assay with the Siemens Coat-
A-Count RIA kit is 8 pg/ml according to the kit manufac-
turer, but the lowest point on the standard curve has a
concentration of 20 pg/ml. Of the 76 E2 measurements
with this assay, actual values for 74 of the samples that
were below 20 pg could not be reported (Figure 1,
column 3). Two of the values (41 and 86 pg/ml) were
above 20 pg/ml, although the corresponding LC-MS/MS
levels were <5 pg/ml.Beckman Coulter ultra-sensitive Estradiol RIA Kit
The E2 assay with this kit has a sensitivity of 2.2 pg/ml
according to the kit manufacturer, but the lowest E2 stan-
dard on the standard curve is 5 pg/ml. Four of the E2 values
with this assay were <5 pg/ml, so the actual values are
unknown. However, of the 70 samples that had E2 values
>5 pg/ml, 8 of the values agreed with and 7 were lower
compared to the corresponding LC-MS/MS levels (Figure 1,
column 4). A total of 55 values exceeded the corresponding
LC-MS/MS levels by 3–13 pg/ml.Roche Diagnostics Elecsys 2010 Estradiol II
Chemiluminescent Immunoassay Kit
This E2 assay, which is carried out on an analyzer, has a
sensitivity of 5 pg/ml, which is the same as the lowest E2
standard on the standard curve. Of the 75 E2 measure-
ments, 5 values were in agreement, and 9 values were
lower, 44 values were higher, and 17 are unknown com-
pared to the corresponding LC-MS/MS levels (Figure 1,
column 5).Pantex Extraction 125I Estradiol RIA Kit
The E2 assay carried out with this kit was the only one
that used a preceding purification step (organic solvent
extraction). The sensitivity of this assay is 10 pg/ml,
which is the same as that of the lowest E2 standard used
in the standard curve. Of the 74 E2 measurements, 62
were <10 pg/ml and the values for these samples could
not be reported. Seven values were below the correspond-
ing LC-MS/MS levels, which ranged from 11 to 20 pg/ml,
and 5 values were from 8–12 pg/ml higher than the corre-
sponding LC-MS/MS levels (Figure 1, column 6).Discussion
The goal of this study was to evaluate the performance of
commercially available E2 immunoassay kits commonly
used to measure E2 levels in the serum of postmenopausal
breast cancer patients treated with AIs. Our results clearly
demonstrate that the investigated kits lacked the sensitivity
and accuracy to detect the extremely low E2 levels in our
patient group.
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breast cancer patients includes estrogen deprivation, either
by blocking estrogen receptors at the target tissues using
selective estrogen receptor modulators (SERMs), e.g.,
tamoxifen, or by decreasing estrogen production through
inhibition of aromatase activity using AIs. In hormone
sensitive breast cancers, hormone manipulation improves
15-year breast cancer mortality. Meta-analyses of rando-
mized controlled trials of AIs versus tamoxifen in post-
menopausal women with early hormone sensitive breast
cancer demonstrated decreased distant recurrence, and
improved cancer related mortality, disease free survival
and event free survival (Coates et al. 2007; Forbes et al.
2008). Overall survival was better in the AI group as
well (RR 0.71; p = 0.04). Additionally safety data from
the Arimidex, Tamoxifen, Alone, or in Combination
(ATAC) trial that compared the AI, anastrozole, with
tamoxifen showed fewer treatment-related adverse events
in the anastrozole treated group (Howell et al. 2005).
In perimenopausal women undergoing hormonal
manipulation for early breast cancer, sequential use of
tamoxifen and AIs has been shown to decrease recurrence
risk over tamoxifen alone by 40% (Dowsett et al. 2010).
Thus, perimenopausal women with low serum estrogen
levels benefit more from aromatase inhibition than
hormone receptor blockade with tamoxifen, when used
either sequentially with tamoxifen or AIs alone. Accurate
measurements of serum E2 levels are key to identifying
which therapy most benefits women in this subgroup.
Lack of compliance, altered pharmacokinetics of drugs,
and unrecognized drug/drug interactions could influence
the degree of suppression of E2 in the individual patient. To
allow optimum clinical decision making, E2 levels have to
be measured and documented properly, requiring highly
sensitive and specific assays. Our study clearly shows that
E2 measurements based on the immunoassay methods that
lack appropriate preceding purification steps do not fulfill
this need. The use of incorrectly performing commercial
E2 kits could lead to misguided clinical decisions based on
inaccurate laboratory data.
The poor performance of the assays obtained with the
E2 immunoassay kits investigated in our study can be
explained by the fact that manufacturers of these kits
generally do not carry out a thorough validation of the
assays obtained with the kits. This is especially true
regarding assay sensitivity and specificity, as evident in the
present study. Assay sensitivity can be defined as the lowest
concentration of a compound that can be distinguished
from a sample that does not contain that compound (the
zero standard). The variation of the zero standard in an
immunoassay can be estimated by assaying replicates of this
standard, e.g., 10 replicates, and calculating the mean
counts bound and the standard deviation. The mean counts
minus 2 standard deviations, read off the assay standardcurve as the concentration (by extrapolation), is the
minimal detection limit. However, manufacturers of steroid
hormone immunoassay kits rarely state how they
determine the assay sensitivity, which is reported in their
package inserts describing the assay validation. Often they
report a sensitivity that is lower than the lowest point on
the standard curve, which they obtain by extrapolation.
This is evident in Table 1, which shows lower values
reported by manufacturers of the Siemens Coat-A-Count
Estradiol RIA, Siemens Double Antibody RIA and
Beckman Couter Ultra-Sensitive RIA. Values measured
below the lowest reliable point on the standard curve
should be reported as being below assay sensitivity. Since in
the present study, the lowest E2 concentration obtained in
the standard curve was 20 pg/ml with three of the kits and
5 pg/ml with the other three kits, E2 levels below these con-
centrations would not be reliable. One of the assays in
which the lowest E2 standard was 5 pg/ml had a sensitivity
of 1.4 pg/ml according to the manufacturer of the kit
(Siemens Double Antibody RIA kit). A total of 72 of the 76
E2 measurements obtained with this assay were <5 pg/ml.
Although at first it appears that this assay is highly sensitive,
we have previously shown that the assay underestimates
the true E2 measurements and lacks specificity (Stanczyk
et al. 2010).
Assay specificity is defined as the degree of interference
or cross-reaction encountered from substances other than
the one that is measured in the assay. The most obvious
potential cross-reacting substances are metabolites of E2,
which include unconjugated metabolites such as estrone
(E1), as well as conjugated metabolites (sulfates and glucu-
ronides) of both E2 and E1. The total number of E2 metabo-
lites is over 100. In addition to potential interference in the
assay by E2 metabolites, AIs and/or one or more of their
numerous metabolites may also cross-react with the anti-
body in the assay. Thus, purification of E2 by use of organic
solvent extraction to remove conjugated metabolites and
chromatography to separate unconjugated metabolites from
E2 prior to its quantitation is essential. This is not done
when commercial immunoassay kits are used to measure
E2, resulting in overestimation of E2 levels as observed in
the present study.
Conclusion
The findings of this study clearly emphasize the need for
improved E2 immunoassay methods, or a complete change
in methodology to ensure accurate and reliable serum E2
measurements for patients undergoing AI treatment. The
LC-MS/MS assay is the purported gold standard for
measuring steroids with high validity. Although this
method is costly, cumbersome, and not widely available
in every hospital setting, LC-MS/MS assays have been
implemented successfully for routine steroid hormone
analysis in major laboratories (e.g., Mayo Clinic, Quest
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To ensure the correct measurement of E2 levels, serum
samples from patients undergoing AI treatment should be
sent to these specialized laboratories.
To summarize, our findings showed that commercially
available and frequently used E2 immunoassay kits lack the
sensitivity and specificity to measure the extremely low
serum E2 levels in postmenopausal breast cancer patients
undergoing AI treatment. Because most clinicians who
treat such patients and send serum samples for E2 measure-
ment to clinical diagnostic laboratories are not familiar with
assay methodology, we would like to draw attention to this
problem that could affect treatment outcome and safety of
patients. Hence, the findings of this study translate into an
immediate clinical need for improved immunoassay
methods or a complete change in methodology so accurate
and reliable serum E2 measurements for AI treated patients
can be ensured.
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